Capabilities by Region: United States
Greenhill has considerable advisory experience in the United States. Our Managing Directors and professionals have advised clients on transactions involving many of the leading companies in the region and have access to a vast network of corporate relationships throughout United States.
Greenhill established its presence in the United States in January 1996 with the opening of our office in New York. Greenhill further expanded its U.S. presence with the opening of Chicago and San Francisco offices in 2008 and the Houston office in 2009.
For more information on Greenhill’s advisory practice in the United States and our capabilities in the region, please contact Chief Executive Officer Scott Bok or President Kevin Costantino in our New York office.
Below we highlight a few of the transactions on which we have advised in this region:
Recent Transactions
Sort By
HIS Company, Inc. (“Hisco”)
Advising Hisco, a leading employee-owned distributor of specialty products serving high growth industrial technology applications, on its sale to Distribution Solutions Group, Inc. (Nasdaq: DSGR), a premier specialty distribution company providing high touch, value-added distribution solutions to the maintenance, repair & operations (MRO), original equipment manufacturer (OEM) and industrial technologies markets
David Brown Santasalo
Advised N4 Partners on the sale of David Brown Santasalo (DBS), UK based industrial gear manufacturer, to Stellex Capital Management
Flavor Specialty Ingredients division of IFF
Sole financial adviser to Exponent, one of the UK’s leading private equity firms, on the acquisition of IFF’s Flavor Specialty Ingredients division, a global leader in the base aromas market
Gaming Services Division of Global Payments
Advising Parthenon Capital, a financial services & technology focused private equity firm, on its acquisition of Global Payment’s Gaming Services Division, a leading provider of on-site and digital payment processing services to companies in the gaming industry, for $415mm
Clinigen Ltd’s Proleukin
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies